Aarti Drugs
Aarti Drugs Performance
Day Range
- Low
- High
52 Week Range
- Low
- High
- Open Price
- Previous Close
- Volume
Start SIP in Aarti Drugs
Start SIPAarti Drugs Investment Rating
-
Master Rating:
-
Aarti Drugs has an operating revenue of Rs. 2,716.05 Cr. on a trailing 12-month basis. An annual revenue growth of 9% is good, Pre-tax margin of 8% is okay, ROE of 13% is good. The company has a reasonable debt to equity of 17%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 8% and 6% from 50DMA and 200DMA. It is currently FORMING a base in its weekly chart and is trading around 8% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 56 which is a POOR score indicating inconsistency in earnings, a RS Rating of 65 which is FAIR indicating the recent price performance, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 111 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.
EPS Strength
Price Strength
Buyer Demand
Group Rank
| Indicator | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 |
|---|---|---|---|---|---|
| Oper Rev Qtr Cr | 696 | 626 | 625 | 551 | 641 |
| Operating Expenses Qtr Cr | 608 | 557 | 555 | 496 | 557 |
| Operating Profit Qtr Cr | 89 | 69 | 70 | 55 | 84 |
| Depreciation Qtr Cr | 12 | 12 | 12 | 12 | 12 |
| Interest Qtr Cr | 8 | 9 | 8 | 7 | 6 |
| Tax Qtr Cr | 16 | 12 | 14 | 10 | 14 |
| Net Profit Qtr Cr | 53 | 37 | 37 | 26 | 53 |
Aarti Drugs Technicals
EMA & SMA
- Bullish Moving Average
- ___
- 16
- Bearish Moving Average
- ___
- 0
- 20 Day
- ₹452.16
- 50 Day
- ₹433.86
- 100 Day
- ₹424.49
- 200 Day
- ₹431.88
- 20 Day
- ₹455.69
- 50 Day
- ₹426.91
- 100 Day
- ₹406.83
- 200 Day
- ₹432.08
Aarti Drugs Resistance and Support
| Resistance | |
|---|---|
| First Resistance | ₹469.97 |
| Second Resistance | ₹479.94 |
| Third Resistance | ₹486.42 |
| RSI | 62.4 |
| MFI | 76.49 |
| MACD Single Line | 8.6 |
| MACD | 8.42 |
| Support | |
|---|---|
| First Resistance | ₹453.52 |
| Second Resistance | ₹447.04 |
| Third Resistance | ₹437.07 |
Aarti Drugs Delivery and Volume
| Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
|---|---|---|---|
| Day | 599,566 | 23,760,801 | 39.63 |
| Week | 488,237 | 13,631,577 | 27.92 |
| 1 Month | 316,340 | 8,284,954 | 26.19 |
| 6 Month | 572,450 | 6,880,847 | 12.02 |
Aarti Drugs Result Highlights
Aarti Drugs Synopsis
NSE-Medical-Diversified
Aarti Drugs Ltd is involved in the business activities of Manufacture of basic chemicals, fertilizer and nitrogen compounds, plastics and synthetic rubber in primary forms. Company’s Total Operating Revenue is Rs. 2497.97 Cr. and Equity Capital is Rs. 92.60 Cr. for the Year ended 31/03/2023. Aarti Drugs Ltd. is a Public Limited Listed company incorporated on 28/09/1984 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L37060MH1984PLC055433 and registration number is 055433.| Market Cap | 4,363 |
| Sales | 2,498 |
| Shares in Float | 3.70 |
| No of funds | 73 |
| Yield | 0.22 |
| Book Value | 3.92 |
| U/D Vol ratio | 1 |
| LTDebt / Equity | 15 |
| Alpha | 0.05 |
| Beta | 0.54 |
Aarti Drugs
| Owner Name | Mar-23 | Dec-22 | Sep-22 | Jun-22 |
|---|---|---|---|---|
| Promoters | 59.58% | 59.66% | 59.77% | 59.98% |
| Mutual Funds | 4.01% | 3.82% | 3.08% | 2.68% |
| Insurance Companies | 0.08% | 0.08% | 0.08% | 0.08% |
| Foreign Portfolio Investors | 1.94% | 1.9% | 1.94% | 2.07% |
| Financial Institutions/ Banks | ||||
| Individual Investors | 25.72% | 25.98% | 26.66% | 32.16% |
| Others | 8.67% | 8.56% | 8.47% | 3.03% |
Aarti Drugs Management
| Name | Designation |
|---|---|
| Mr. Chandrakant V Gogri | Chairman Emeritus |
| Mr. Prakash M Patil | Chairman & M.D & CEO |
| Mr. Rashesh C Gogri | Managing Director |
| Mr. Harshit M Savla | Joint Managing Director |
| Mr. Harit P Shah | Executive Director |
| Mr. Uday M Patil | Executive Director |
| Mr. Neha R Gada | Non Executive Director |
| CA. Navin C Shah | Independent Director |
| Dr. Krishnacharya G Akamanchi | Independent Director |
| Prof. Bhaskar N Thorat | Independent Director |
| CA. Priti P Savla | Independent Director |
Aarti Drugs Forecast
Price Estimates
Aarti Drugs Corporate Action
| Date | Purpose | Remarks |
|---|---|---|
| 2023-04-29 | Audited Results | |
| 2023-01-27 | Quarterly Results & Interim Dividend | |
| 2022-10-20 | Quarterly Results | |
| 2022-07-27 | Quarterly Results | |
| 2022-05-09 | Audited Results |
| Date | Purpose | Remarks |
|---|---|---|
| 2023-02-08 | INTERIM | Rs.1.00 per share(10%)Interim Dividend |
| 2022-02-10 | INTERIM | Rs.1.00 per share(10%)Interim Dividend |
Aarti Drugs FAQs
What is Share Price of Aarti Drugs ?
Aarti Drugs share price is ₹471 As on 08 June, 2023 | 00:04
What is the Market Cap of Aarti Drugs ?
The Market Cap of Aarti Drugs is ₹4362.8 Cr As on 08 June, 2023 | 00:04
What is the P/E ratio of Aarti Drugs ?
The P/E ratio of Aarti Drugs is 26.2 As on 08 June, 2023 | 00:04
What is the PB ratio of Aarti Drugs ?
The PB ratio of Aarti Drugs is 3.7 As on 08 June, 2023 | 00:04